GC Biopharma Corp.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GC Biopharma Corp.
Aside from a mixed bag of second-quarter earnings, the latest developments in the Korean pharma industry include Hanmi’s search for new indications for u-turned assets and the approval of Yuhan’s lazertinib as a first-line treatment for NSCLC.
Highlighted by SK Biopharmaceuticals’ recent decision to acquire the US-based ProteoVant Sciences, Korean pharma firms are stepping up deals and collaborations in the hot TPD space, which is expected to continue to attract global investors and big pharma interest.
As the global economy remains in a slump, even big pharmas such as Novartis and Pfizer are cutting costs. So how should Korean biopharmas adapt to such an environment and move ahead? Korea Drug Development Fund CEO H. Samuel Muk provides some ideas on how domestic players can survive in this new global reality.
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
- Contract Manufacturing Organization
- Other Names / Subsidiaries
- Ceragem Medisys
- Green Cross LabCell
- Green Cross Corporation
- GC Pharma
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.